OXiGENE is a biopharmaceutical company developing new and improved therapeutics that deliver significant medical benefits to patients with cancer and sight-threatening eye diseases and conditions.

Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is ZYBRESTAT®. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor hypoxia and tumor cell death. Because our VDAs target the tumor vasculature rather than the tumor cells they have broad potential therapeutic utility in cancer. They may also be effective in certain vascularization-dependent eye disease and potentially other diseases/conditions. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are non-competitive and potentially complementary with anti-angiogenic drugs and chemotherapeutic agents.

OXiGENE has ongoing VDA drug development programs that address cancer and ophthalmology indications. As described in scientific publications and presentations, our VDA product candidates have demonstrated significant potential in human clinical studies to date in cancer and eye disease.